Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Autoimmunecase reportClinicalDiagnosisGlomerulonephritisimmune complexpatient careRenalRheumatoid arthritisrheumatologyTNF-Alpha inhibitor

Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

Thomas R. Collins  |  June 13, 2016

CHICAGO—Nine out of 10 scleroderma cases include clinical signs of gastrointestinal (GI) involvement, with severe involvement associated with high mortality rates, but the pathology of this is not very well understood, a GI expert said at the ACR’s State-of-the-Art Clinical Symposium. That has left clinicians with a slate of treatments—anti-reflux, antimicrobials and prokinetics—that address only…

Filed under:ConditionsResearch RheumSystemic Sclerosis Tagged with:2016 State-of-the-Art Clinical Symposiumgastrointestinalpatient careResearchSclerodermaTreatment

Email Remains Dominant Communications Method in Medicine

Richard Quinn  |  June 13, 2016

Forty-five years ago, a computer engineer in Boston sent an electronic message between two computers some 10 feet apart. It took another 10 years or so before the electronic mail message was dubbed email—a term now, perhaps, more ubiquitous than any other in the lexicon of modern communications. Despite the seemingly definitive place email communication…

Filed under:Practice SupportProfessional TopicsTechnology Tagged with:communicationemailFacebookGoogleHIPPAITpatient carephysicianprivacyrheumatologistSecuritySocial MediaTechnologyTwitter

The ACR’s Collaboration with International Rheumatology Associations Promotes Progress

Joan M. Von Feldt, MD, MSEd, FACR, FACP, & Elizabeth A. Schlenk, PhD, RN  |  June 12, 2016

More than 10 years ago, New York Times journalist Thomas Friedman opined an old-world perspective that the world is, in fact, flat. In an article published on April 3, 2005, Mr. Friedman contended that “Individuals must, and can, now ask: Where do I fit into the global competition and opportunities of the day, and how…

Filed under:Education & TrainingEULAR/OtherMeeting ReportsPresident's Perspective Tagged with:AC&RAFLARAmerican College of Rheumatology (ACR)APLAR Asia PacificAssociation of Rheumatology Professionals (ARP)collaborationEducationEULARglobalILARInternationalPANLARprogressrheumatology

Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

Michele B. Kaufman, PharmD, BCGP  |  June 8, 2016

In a clinical trial, patients with osteoarthritis taking low-dose SoluMatrix meloxicam used less rescue medication to manage pain. Also, the FDA has issued a new warning against using oral ketoconazole off label to treat onychomycosis and fungal skin infections…

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyFDAFood and Drug AdministrationketoconazolemeloxicamOsteoarthritisPainsafety warning

Running Barefoot May Protect Against Some Musculoskeletal Injuries

Lara C. Pullen, PhD  |  May 23, 2016

Running barefoot may conjure images of summer and childhood, but since Abebe Bikila of Ethiopia set a world record running barefoot in the marathon in the 1960 Olympic Games in Rome (Olympic gold medal in a world-record 2:15:16.2), many runners have adopted the style. A recent study found that running barefoot may be associated with significantly fewer overall musculoskeletal injuries than running shod…

Filed under:Conditions Tagged with:ExercisefeetinjuryMusculoskeletalpodiatry

Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More

Michele B. Kaufman, PharmD, BCGP  |  May 13, 2016

April 5, 2016, marks a revolutionary day in the treatment of autoimmune diseases: The U.S. Food and Drug Administration (FDA) approved an infliximab (Remicade) biosimilar, known as Inflectra (infliximab-dyyb). Infliximab-dyyb, which is administered by intravenous infusion, is the first biosimilar drug approved to treat rheumatic disease in the U.S.1 Infliximab-dyyb has received approval for almost…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:ApprovalsBiologicsBiosimilarsdrugFDAInflectrainfliximabRemicadeResearchrheumatologySafetyZirletta

Treating Rheumatologic Illnesses in Athletes

Treating Rheumatologic Illnesses in Athletes

Simon M. Helfgott, MD  |  May 13, 2016

Never underestimate the power of dreams and the influence of the human spirit. … The potential for greatness lives within each of us. —Wilma Rudolph, U.S. Olympic sprinter & winner of three gold medals From Spinnaker to Wheelchair It can be an unnerving experience when the patient you are about to see is young and…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:athletespolyarthritisrheumatologistrheumatologyTreatment

Tips for Setting Treatment Goals with the Patient

Karen Appold  |  May 13, 2016

When working with a newly diagnosed patient to determine a treatment plan, ensure the patient has a good understanding of the diagnosis, the options available and what the options entail. “It is important to help patients understand that there are choices, and that their decisions should be based on what matters to them,” says Susan…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:patient carerheumatologistrheumatologytreatment goals

Tips for Increasing Your Client Base

Karen Appold  |  May 13, 2016

Recruiting new patients requires a multi-faceted approach. A rheumatologist must have a solid brand and marketing platform, as well as an active strategy to attract and convert new patients. This might involve embracing social media, having a website, developing a referral network, being involved in your community and nurturing existing patients. Your brand includes such…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:patient carePatientsPractice Managementrheumatology

  • « Previous Page
  • 1
  • …
  • 128
  • 129
  • 130
  • 131
  • 132
  • …
  • 162
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences